Curis Inc (CRIS) stock
CRISNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.45−0.13 (-22.18%)
Close on Nov 13, 2026Market cap $930.08KP/E –Yield –
Curis ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Curis's ebitda for the twelve months ending Sep 30, 2026 was -$10.53M. For fiscal 2025 it was -$5.54M. The highest annual figure on record is -$4.95M in fiscal 2010.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$5.54M | – |
| FY2024 | Dec 31, 2024 | -$44.34M | – |
| FY2023 | Dec 31, 2023 | -$48.08M | – |
| FY2022 | Dec 31, 2022 | -$52.79M | – |
| FY2021 | Dec 31, 2021 | -$41.91M | – |
| FY2020 | Dec 31, 2020 | -$24.75M | – |
| FY2019 | Dec 31, 2019 | -$24.23M | – |
| FY2018 | Dec 31, 2018 | -$29.16M | – |
| FY2017 | Dec 31, 2017 | -$49.53M | – |
| FY2016 | Dec 31, 2016 | -$57.85M | – |
| FY2015 | Dec 31, 2015 | -$56.32M | – |
| FY2014 | Dec 31, 2014 | -$15.71M | – |
| FY2013 | Dec 31, 2013 | -$9.27M | – |
| FY2012 | Dec 31, 2012 | -$18.49M | – |
| FY2011 | Dec 31, 2011 | -$7.10M | – |
| FY2010 | Dec 31, 2010 | -$4.95M | – |
| FY2009 | Dec 31, 2009 | -$9.29M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$8.74M | – |
| Q2 FY2026 | Jun 30, 2026 | -$9.93M | – |
| Q1 FY2026 | Mar 31, 2026 | -$11.51M | – |
| Q4 FY2025 | Dec 31, 2025 | $19.66M | – |
| Q3 FY2025 | Sep 30, 2025 | -$6.89M | – |
| Q2 FY2025 | Jun 30, 2025 | -$8.21M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.10M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.98M | – |
| Q3 FY2024 | Sep 30, 2024 | -$10.51M | – |
| Q2 FY2024 | Jun 30, 2024 | -$12.45M | – |
| Q1 FY2024 | Mar 31, 2024 | -$12.41M | – |
| Q4 FY2023 | Dec 31, 2023 | -$12.14M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.31M | – |
| Q2 FY2023 | Jun 30, 2023 | -$12.07M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.56M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.13M | – |
| Q3 FY2022 | Sep 30, 2022 | -$12.55M | – |
| Q2 FY2022 | Jun 30, 2022 | -$15.02M | – |
| Q1 FY2022 | Mar 31, 2022 | -$15.10M | – |
| Q4 FY2021 | Dec 31, 2021 | -$12.53M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.01M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.61M | – |
| Q1 FY2021 | Mar 31, 2021 | -$8.76M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.25M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.66M | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.39M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.46M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.31M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.29M | – |
| Q2 FY2019 | Jun 30, 2019 | -$6.11M | – |
| Q1 FY2019 | Mar 31, 2019 | -$5.52M | – |
| Q4 FY2018 | Dec 31, 2018 | -$5.11M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.38M | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.81M | – |
| Q1 FY2018 | Mar 31, 2018 | -$9.86M | – |
| Q4 FY2017 | Dec 31, 2017 | -$7.07M | – |
| Q3 FY2017 | Sep 30, 2017 | -$14.41M | – |
| Q2 FY2017 | Jun 30, 2017 | -$13.05M | – |
| Q1 FY2017 | Mar 31, 2017 | -$15.00M | – |
| Q4 FY2016 | Dec 31, 2016 | -$10.71M | – |
See a number that looks wrong?